Looks like U of M is preparing to treat MSS CRC pts. with CNS lesions. The OR they saw in pts without CNS lesions must be significant. They are using FT 536 in GBM pts as POC. Exclusion: Received prior treatment with bevacizumab or any other cellular therapy available on or off a clinical trial.
Market Data 
Markets 
